Botswana and an American biotech firm, Ginkgo Bioworks, have partnered to conduct pathogen surveillance at the country’s entry points. Health officials say the proactive move is meant to safeguard public health as the world faces emerging disease threats.
Botswana introduced mpox screening last month for travelers at its entry points.
In a statement Wednesday, Ministry of Health spokesperson Christopher Nyanga said a pathogen-monitoring program is critical to detecting similar emerging health threats.
Dr. Mbatshi Mazwiduma, a public health expert, said the pathogen-surveillance program will complement existing strategies to prevent disease threats.
“The initiative by the Ministry of Health is a very welcome development in the sense that it is at least demonstrating that they are both embracing traditional methods of surveillance and disease detection plus at the same time, they are looking at other innovative ways of disease detection,” he said.
Through the collaboration, Boston-based Gingko Bioworks will work with the Ministry of Health to collect and monitor travelers’ samples. Nasal swabs will be used to collect the samples.
Nyanga said testing will be done on a voluntary, anonymous basis.
“Although participation in this initiative is entirely voluntary, travelers are encouraged to participate because this early detection of pathogens is meant to safeguard the health of all citizens, visitors and residents of this country,” he said. “The samples collected will be kept anonymous. The data collected from the samples will be vital in strengthening the country’s robust health system and response to public health threats and emergencies.”
But Mazwiduma said voluntary participation in the pathogen-monitoring program could hinder effective disease detection.
“Perhaps if non-invasive, non-intrusive, the technique should be compulsory because it ensures that the number of people who comply to sample acquisition is increased and, therefore, you can actually rapidly achieve suitable sample sizes for you to be able to ensure that you do not miss any patients, but also more importantly that it allows you to improve your validation of these particular technologies,” Mazwiduma said.
Botswana and Gingko Bioworks previously collaborated in a 2022 pathogen-monitoring program to detect new and emerging COVID-19 variants.
During the same year, Botswana was credited with the discovery of COVID-19 variant omicron.
